Aamund wants to invest in drug development
Asger Aamund has a very clear plan for his investment strategy following the sale of all his shares in Bavarian Nordic. Read more about the reason for the sale and about one issue that “really bugs him”.
BY HENRIK TÜCHSEN
The Danish biotech pioneer Asger Aamund has money to burn once again following the major sale of shares in Bavarian Nordic, the biotech company he founded about 20 years ago.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Aamund: We have reached the pearly gates
For abonnenter
Aamund steps down as Chairman
For abonnenter
